Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

CareVet-Logo-New
04/12/2021

CareVet Challenges Industry to Adopt $15/hr Minimum Pay

READ MORE
C4-logo-400
04/10/2021

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

READ MORE
CareVet-Logo-New
04/09/2021

Living wage initiative launched by national hospital network

READ MORE
CareVet-Logo-New
04/01/2021

Raising the Ante

READ MORE
wugen-logo-400
03/25/2021

The Development of Natural Killer Cells for Solid Tumor Treatment

READ MORE
Logo-Geneoscopy-400
03/17/2021

Geneoscopy Appoints Don Hardison to its Strategic Advisory Board

READ MORE
wugen-logo-400
03/11/2021

Alpha Biopharma lands deal for Wugen’s memory NK and CAR T cells for Asia

READ MORE
C4-logo-400
03/11/2021

C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results

READ MORE
C4-logo-400
03/10/2021

C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300